BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29938458)

  • 1. Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
    Choi J; Chung T; Rhee H; Kim YJ; Jeon Y; Yoo JE; Noh S; Han DH; Park YN
    Gut Liver; 2019 Jan; 13(1):83-92. PubMed ID: 29938458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
    Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
    J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma.
    Huang WJ; Jeng YM; Lai HS; Fong IU; Sheu FY; Lai PL; Yuan RH
    PLoS One; 2015; 10(3):e0119181. PubMed ID: 25738958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.
    Ninomiya G; Yamada S; Hayashi M; Takeda S; Suenaga M; Takami H; Kanda M; Iwata N; Niwa Y; Tanaka C; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Oncol Rep; 2018 Jun; 39(6):2664-2672. PubMed ID: 29620290
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
    Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
    Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization.
    Rhee H; Nahm JH; Kim H; Choi GH; Yoo JE; Lee HS; Koh MJ; Park YN
    Mod Pathol; 2016 Sep; 29(9):1038-49. PubMed ID: 27312064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
    Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
    J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
    Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
    Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
    Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
    Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
    Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
    Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
    Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting.
    Radić J; Kožik B; Nikolić I; Kolarov-Bjelobrk I; Vasiljević T; Vranjković B; Despotović S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer.
    Zhan P; Lv XJ; Ji YN; Xie H; Yu LK
    Clin Respir J; 2018 Feb; 12(2):712-720. PubMed ID: 27860390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
    Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
    Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
    Kang HJ; Kim IH; Sung CO; Shim JH; Yu E
    Virchows Arch; 2015 Apr; 466(4):403-13. PubMed ID: 25577552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.